StonvexLoading…
StonvexStonvexStonvexCore line items from CYTK's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $19.36M | $88.04M | $70.28M | $68.35M |
Operating Income | $-183.62M | $-612.26M | $-433.89M | $-267.14M |
Net Income | $-206.03M | $-784.96M | $-601.92M | $-134.37M |
EPS (Diluted) | $-1.67 | $-6.54 | $-5.04 | $-2.49 |
Total Assets | $1.27B | $1.42B | $1.44B | $1.23B |
Total Liabilities | $2.10B | $2.08B | $1.96B | $1.59B |
Cash & Equivalents | $129.84M | $122.52M | $225.47M | $74.94M |
Free Cash Flow OCF − CapEx | $-151.39M | $-534.82M | $-386.52M | $-269.66M |
Shares Outstanding | 123.27K | 122.94M | 119.32K | 118.98K |